Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Investors Business Daily • 602 days
Low Materiality0/10
Information
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an au...
Original sourceAI Summary
- FDA approval of Vyvgart Hytrulo for CIDP led to surge in Argenx stock. - Approval indicates potential growth for Argenx in treating autoimmune conditions. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Corporate Developments
Market-Moving
- FDA approval of Vyvgart Hytrulo for CIDP led to surge in Argenx stock.
- Approval indicates potential growth for Argenx in treating autoimmune conditions.
Key Facts
- FDA approval of Vyvgart Hytrulo for CIDP led to surge in Argenx stock.
- Approval indicates potential growth for Argenx in treating autoimmune conditions.